Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.
Hologic, Inc. (Nasdaq: HOLX) generates a steady flow of news centered on women’s health, medical technology innovation and corporate developments. As a company that describes itself as focused on developing technologies to detect, diagnose and treat health conditions, many of its announcements highlight advances in diagnostics, breast imaging, oncology testing and digital pathology.
Investors and healthcare professionals following HOLX news will find updates on Hologic’s diagnostic platforms, such as the Panther and Panther Fusion systems, including regulatory milestones like FDA clearance and CE marking for new assays. Recent communications have covered automated molecular tests for gastrointestinal bacterial pathogens, which expand the company’s infectious disease testing menu and illustrate its emphasis on rapid, molecular-based diagnostics.
Hologic’s news feed also features developments in breast health technologies. The company has publicized data on its AI-powered mammography tools, such as the Genius AI Detection solution and 3DQuorum imaging technology, through studies conducted at major medical centers and presented in peer-reviewed journals or at scientific meetings. These stories often focus on how artificial intelligence can support radiologists by flagging suspicious areas on mammograms and streamlining image review without compromising cancer detection performance.
Oncology and precision medicine are recurring themes. Hologic and its subsidiary Biotheranostics, Inc. issue updates about the Breast Cancer Index Test, including new clinical evidence presented at conferences like the San Antonio Breast Cancer Symposium. These releases describe how the test may inform extended endocrine therapy decisions for patients with early-stage, hormone receptor–positive breast cancer and examine its performance in various patient subgroups.
Beyond technology and clinical data, Hologic’s news includes educational initiatives and partnerships, such as the "Ultimate Defense" cervical cancer screening awareness campaign with professional basketball player Erica Wheeler, and collaborations in epigenomics and pharmaco-epigenetics through Hologic Diagenode and co-marketing agreements. Corporate and financial announcements, including quarterly earnings releases and the proposed acquisition of Hologic by funds managed by Blackstone and TPG, provide additional context for HOLX stockholders.
For readers interested in HOLX news, this page offers a centralized view of Hologic’s product milestones, clinical research, public health campaigns and transaction-related updates, making it a useful resource for tracking how the company’s activities evolve over time.
Hologic (Nasdaq: HOLX) launched Ultimate Defense, a U.S. educational campaign with professional basketball player Erica Wheeler to raise awareness of routine cervical cancer screening and encourage conversations with healthcare providers.
The campaign debuts during Cervical Health Awareness Month (January 2026) with a public service announcement and social content urging Pap and HPV co-testing per U.S. guidelines for ages 21–65 and directing people to YourUltimateDefense.com for resources.
Hologic (Nasdaq: HOLX) reported a retrospective study of 7,500 digital breast tomosynthesis screening exams (2016–2019) using Genius AI Detection 2.0 that examined false-negative and cancer cases.
The AI flagged approximately 32% of 100 false-negative exams and correctly localized suspicious areas; it also flagged almost 90% of 500 radiologist-identified cancer cases and localized their locations. The algorithm more often flagged invasive ductal and lymph node–positive cancers and less often flagged invasive lobular and grade I cancers.
Study limits include a single academic center, a predominantly Caucasian population, small subgroup sizes, and no evaluation of patient outcomes or real-world workflow integration.
Hologic (Nasdaq: HOLX) announced 11 studies featuring the Breast Cancer Index (BCI) Test to be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) on December 10–11, 2025. The data explore expanded utility in premenopausal women, comparative analyses versus the 21-gene assay, and consistency across sample types.
Key highlights include a translational analysis of the SOFT and TEXT trials suggesting BCI may identify premenopausal patients at minimal distant-recurrence risk and a registry analysis showing BCI can re-stratify 21-gene assay risk groups. The company cites >9,000 providers using BCI and multiple real-world and independent studies supporting clinical decision-making for extended endocrine therapy.
Hologic (Nasdaq: HOLX) will present new clinical evidence at RSNA on November 25, 2025 showing real-world performance of its AI-powered mammography tools.
Key findings: a retrospective study of >160,000 screening exams found no significant change in cancer detection after implementing 3DQuorum imaging, which reduces 3D slices radiologists review; a separate reader study found Genius AI Detection detected more cancers but had lower specificity. Hologic will demonstrate Genius AI Detection, Envision Mammography Platform, and host medical education sessions at RSNA.
Hologic (Nasdaq: HOLX) announced on November 12, 2025 that its Genius Digital Diagnostics System received expanded CE marking in the European Union to enable whole slide imaging for both cell and tissue specimens.
The expansion allows European labs to digitize entire slides across a wider range of specimen types, unify workflows on a single platform, and use new software capabilities including remote support, LIS readiness and additional review tools. Whole slide imaging remains not available in the United States, and commercialization will be announced by country.
Hologic (Nasdaq: HOLX) entered into a definitive agreement to be acquired by funds managed by Blackstone and TPG for $76 per share in cash plus a non-tradable contingent value right (CVR) of up to $3 per share, for total consideration of up to $79 per share. The deal values Hologic at an enterprise value of up to $18.3 billion and represents about a 46% premium to Hologic’s closing price on May 23, 2025. The transaction includes minority investments from ADIA and GIC, has committed financing, a 45-day go-shop, and is expected to close in H1 2026 pending approvals. Upon closing, Hologic common stock will be delisted from Nasdaq.
Hologic (Nasdaq: HOLX) will release its fourth-quarter fiscal 2025 financial results on Monday, November 3, 2025 after the market close. Management will host a conference call the same day at 4:30 p.m. Eastern Time.
Investors can join by phone (US/Canada: 800-330-6710; International: +1 312-471-1353, access code 5756948) or via the live webcast on Hologic’s investor site. Dial-in is recommended 5–10 minutes early. A replay will be posted on investors.hologic.com approximately two hours after the call and remain available for 30 days.
Hologic (NASDAQ: HOLX) has achieved a significant regulatory milestone with both FDA 510(k) clearance and CE marking for its new Panther Fusion® Gastrointestinal (GI) Bacterial and Expanded Bacterial Assays. These molecular diagnostic tests are designed to detect common bacterial pathogens causing infectious gastroenteritis.
The tests can identify multiple pathogens including Salmonella, Campylobacter, Shigella, E. coli, Vibrio, Yersinia, and Plesiomonas. Running on Hologic's Panther Fusion System, these customizable mini-panel assays offer faster, more efficient testing compared to traditional methods, supporting antimicrobial stewardship and enabling targeted treatment decisions.
The technology addresses a significant health concern, as the U.S. experiences nearly 200 million cases of infectious gastroenteritis annually, with up to 3 million requiring ambulatory visits.
Hologic (NASDAQ: HOLX), a global women's health leader, revealed concerning survey results as it prepares to mark Breast Cancer Awareness Month. A Harris Poll survey of over 1,100 U.S. women showed that 48% of recommended women skip or delay mammograms, despite breast cancer having a 99% survival rate when detected early.
The survey uncovered significant misconceptions: 24% of women aged 18-39 incorrectly believe a healthy lifestyle eliminates breast cancer risk, 66% are unaware that dense breasts increase cancer risk, and 27% don't know that yearly mammograms should begin at age 40. In response, Hologic is expanding its #BustTheMyth campaign to educate women about breast cancer screening through various media channels and educational materials.
FAQ
What is the current stock price of Hologic (HOLX)?
What is the market cap of Hologic (HOLX)?
